Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Current Deferred Revenue (2016 - 2017)

Historic Current Deferred Revenue for Aptevo Therapeutics (APVO) over the last 3 years, with Q2 2017 value amounting to $1.4 million.

  • Aptevo Therapeutics' Current Deferred Revenue rose 26649.75% to $1.4 million in Q2 2017 from the same period last year, while for Jun 2017 it was $1.4 million, marking a year-over-year increase of 26649.75%. This contributed to the annual value of $811000.0 for FY2016, which is 7889.67% down from last year.
  • Per Aptevo Therapeutics' latest filing, its Current Deferred Revenue stood at $1.4 million for Q2 2017, which was up 26649.75% from $878000.0 recorded in Q1 2017.
  • Over the past 5 years, Aptevo Therapeutics' Current Deferred Revenue peaked at $3.8 million during Q4 2015, and registered a low of $394000.0 during Q2 2016.
  • For the 3-year period, Aptevo Therapeutics' Current Deferred Revenue averaged around $1.3 million, with its median value being $844500.0 (2016).
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first crashed by 7889.67% in 2016, then surged by 26649.75% in 2017.
  • Quarter analysis of 3 years shows Aptevo Therapeutics' Current Deferred Revenue stood at $3.8 million in 2015, then crashed by 78.9% to $811000.0 in 2016, then soared by 78.05% to $1.4 million in 2017.
  • Its last three reported values are $1.4 million in Q2 2017, $878000.0 for Q1 2017, and $811000.0 during Q4 2016.